Axogen, Inc. AXGN
Axogen, Inc. (AXGN) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $225.2M at a -7.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-04-29 | Canaccord Genuity | Buy (main) |
| 2026-04-29 | Citizens | Market Outperform (main) |
| 2026-04-29 | Wells Fargo | Overweight (main) |
| 2026-04-29 | HC Wainwright & Co. | Buy (main) |
| 2026-04-23 | Lake Street | Buy (main) |
| 2026-03-30 | Canaccord Genuity | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.437 |
| Retained earnings / assets | -1.385 |
| EBIT / assets | -0.035 |
| Equity / liabilities | 1.388 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AXGN | Axogen, Inc. | 5/9 | -0.43 | — | +20.2% |
| OM | Outset Medical, Inc. | 6/9 | -9.87 | — | +5.1% |
| BLFS | BIOLIFE SOLUTIONS INC | 6/9 | 10.32 | — | +28.9% |
| VASO | VASO Corp | 6/9 | 0.72 | 21.3 | +2.7% |
| CBLL | Ceribell, Inc. | 3/9 | 3.97 | — | +36.1% |
| FOCL | EDAP TMS SA | 3/9 | -5.4 | — | +1.6% |
| ELMD | Electromed, Inc. | 6/9 | 10.99 | 46.4 | +17% |
About Axogen, Inc.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
FAQ
Is AXGN financially healthy?
Axogen, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does AXGN pay a dividend?
No, Axogen, Inc. does not currently pay a dividend.
How profitable is AXGN?
In FY2025, Axogen, Inc. had a net margin of -7.0% and a return on equity of -12.2%.
What is the analyst price target for AXGN?
The average Wall-Street price target for Axogen, Inc. is $50.78, about 2.2% above the recent price, from 9 analysts.
Is AXGN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Axogen, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.